Most potent antiretroviral drugs (e.g., HIV-1 protease inhibitors) poorly penetrate the blood-brain barrier. Brain distribution can be limited by the efflux transporter, P-glycoprotein (P-gp). The ability of a novel drug delivery system (block co-polymer P85) that inhibits P-gp, to increase the efficacy of antiretroviral drugs in brain was examined using a severe combined immunodeficiency (SCID) mouse model of HIV-1 encephalitis (HIVE). Severe combined immunodeficiency mice inoculated with HIV-1 infected human monocyte-derived macrophages (MDM) into the basal ganglia were treated with P85, antiretroviral therapy (ART) (zidovudine, lamivudine and nelfinavir (NEL)), or P85 and ART. Mice were killed on days 7 and 14, and brains were evaluated for levels of viral infection. Antiviral effects of NEL, P85, or their combination were evaluated in vitro using HIV-1 infected MDM and showed antiretroviral effects of P85 alone. In SCID mice injected with virus-infected MDM, the combination of ART-P85 and ART alone showed a significant decrease of HIV-1 p24 expressing MDM (25% and 33% of controls, respectively) at day 7 while P85 alone group was not different from control. At day 14, all treatment groups showed a significant decrease in percentage of HIV-1 infected MDM as compared with control. P85 alone and combined ART-P85 groups showed the most significant reduction in percentage of HIV-1 p24 expressing MDM (8% to 22% of control) that were superior to the ART alone group (38% of control). Our findings indicate major antiretroviral effects of P85 and enhanced in vivo efficacy of antiretroviral drugs when combined with P85 in a SCID mouse model of HIVE.
Introduction
Resistance to antiretroviral compounds such as the anti-HIV-1 protease inhibitors can develop and HIV-1 levels rapidly rebound to pretreatment levels if antiretroviral therapy (ART) is discontinued. The appearance of resistance and virus resurgence is related to the limited transport of antiretroviral drugs across tissue barriers and formation of virus reservoirs in long living cells (like macrophages). The blood-brain barrier (BBB) restricts the passage of macromolecules and a number of therapeutic agents, creating an immunologic and pharmacological sanctuary site for HIV-1 in the brain and spinal cord (Aweeka et al, 1999; Pomerantz, 2002) . There is growing evidence indicating that transport proteins expressed at the BBB also regulate penetration of antiretroviral drugs into the central nervous system (CNS) . Allelic variants and inhibition (or induction) of these transporters are determinants of active drug present in the cell (Fellay et al, 2002) . One of these transport proteins, a membrane-associated ATP-dependent efflux transporter, P-glycoprotein (P-gp), is expressed in brain microvascular endothelial cells, and it limits entry into the brain of numerous xenobiotics, including HIV-1 protease inhibitors. In addition, the expression of P-gp was recently shown in brain parenchyma cells, such as resident brain macrophages, the microglia (Lee et al, 2001) . Thus, the cellular membranes of brain macrophages may act as an additional 'barrier' to drug permeability (Bendayan et al, 2002) . This may be important in the treatment of HIV-1 infection of the CNS where macrophages and microglia are the main reservoir for virus . P-glycoprotein is downregulated on brain microvascular endothelial cells during HIV-1 encephalitis (HIVE) . However, P-gp upregulation was shown in brain macrophages during HIVE and in HIV-1 infected macrophages in vitro (Langford et al, 2004; Persidsky et al, 2006) . P-glycoprotein decreased protease inhibitor uptake by HIV-1 infected CD4 + T lymphocytes (Jones et al, 2001) , and it has been previously shown that the protease inhibitors ritonavir, saquinavir, indinavir, amprenavir, and nelfinavir (NEL) are substrates for P-gp (Choo et al, 2000; Kim et al, 1998; Lee et al, 1998; Polli et al, 1999) . If enhanced levels of antiretroviral drugs are to penetrate the BBB into the CNS, inhibition of active efflux components, including P-gp, appear to be necessary (Huisman et al, 2001; Kim et al, 1998) .
Potentially important P-gp inhibitors are known and include the Pluronic block co-polymers such as P85. Prior studies on cells derived from multidrug resistant tumors showed that Pluronics can inhibit the P-gp efflux pump, thereby increasing accumulation of drug in cancer cells (Alakhov et al, 1996) . Such effects could be because of interactions of the Pluronic with the membrane or ATPase function necessary for P-gp efflux activity (Alakhov et al, 1996; Slepnev et al, 1992) . P85 has been shown to diminish ATPase activity in cell membranes expressing P-gp (Batrakova et al, 2001a) . P85 inhibits P-gp on the BBB in vivo as shown by increased concentrations of digoxin (a well-known substrate for P-gp) in mouse CNS (Batrakova et al, 2001b) . Although increased penetration of the protease inhibitor, NEL, into brain was shown by P-gp inhibition in mice (Choo et al, 2000) , there have been no reports on the efficacy of antiretroviral drugs with P-gp inhibition on HIV-1 replication in brain.
The use of animal models to monitor antiretroviral efficacy in the brain is crucial to screening antiretroviral regimens (McArthur and Kieburtz, 2000) . Ascertaining the efficacy of anti-HIV-1 formulations has been made possible by the use of the severe combined immunodeficiency (SCID) mouse model for HIVE, which was developed in our laboratories (Persidsky et al, 1996) . This has been proved of significant value in testing antiretroviral and adjunctive therapies for HIV disease within the CNS (Dou et al, 2003; Limoges et al, 2000 Limoges et al, , 2001 Persidsky et al, 2001) . Severe combined immuno-deficiency mice, injected in the basal ganglia with human HIV-1-infected monocyte-derived macrophages (MDM), show cognitive, behavioral, electrophysiological, immune, and histopathological features of human disease (Anderson et al, 2003; Persidsky et al, 1997 Persidsky et al, , 1996 Zink et al, 2002) . The HIVE SCID mouse model allows the spreading of viral infection in MDM behind an intact BBB, and it was utilized for efficacy testing of antiretroviral agents (Limoges et al, 2000 . To explore the idea that inhibition of efflux will enhance the efficacy of anti-HIV drugs, we assessed whether P-gp inhibition by the Pluronic block copolymer P85 could enhance the efficacy of a protease inhibitor (NEL) in vitro in HIV-1 infected MDM and the efficacy of ART (including zidovudine (AZT), lamivudine (3TC), and NEL) in HIVE SCID mice. The current study showed enhanced CNS efficacy of antiretroviral drugs when combined with P85. Our experiments also showed that there is a significant antiretroviral effect of the block copolymer P85 both in vitro and in vivo, which warrants further investigation.
Materials and methods

Isolation, Culture and Virus Infection of Human Monocyte-Derived Macrophages
Human monocytes were isolated from HIV-1, 2 and hepatitis B seronegative donors and purified by countercurrent centrifugal elutriation (Gendelman et al, 1988) . Monocytes were cultured in 96-well plates or Teflon flasks 2 Â 10 6 cells/mL in Dulbecco's modified Eagle's medium (Sigma Chemical Co., St Louis, MO, USA) with 10% heat inactivated human serum, 1% glutamine, 50 mg/mL gentamicin (Sigma), 10 mg/mL ciprofloxacin (Sigma), and 1000 U/mL human macrophage colony-stimulating factor (a generous gift from Genetics Institute, Inc., Cambridge, MA, USA). After 7 days in suspension culture, MDM were infected with the macrophage-tropic viral strain HIV-1 ADA at an MOI of 0.01 infectious viral particles/target cell (Gendelman et al, 1988) .
Assay of Progeny Virion Production
Reverse transcriptase (RT) activity was determined in triplicate with culture fluids added to 0.05% Nonidet P-40 (Sigma), 10 mg/mL poly(A), 0.25 mg/mL oligo(dt) (Pharmacia Fine Chemicals, Piscataway, NJ, USA), 5 mmol/L dithiothreitol thymidine 5 0 -triphosphate (2 Ci/mmol; Amersham Corp., Arlington Heights, IL, USA) in pH 7.9 Tris-HCl buffer for 24 h at 371C. Radiolabeled nucleotides were precipitated with cold 10% trichloroacetic acid and 95% ethanol in an automatic cell harvester (Skatron Inc., Sterling, VA, USA) on paper filters. Radioactivity was determined by scintillation spectroscopy. Reverse transcriptase results were normalized to cell numbers by measuring cell viability at the end of the sample collection by MTT assay (Limoges et al, 2000) .
Effect of P85 on BBB Integrity In Vivo
To determine if P85 has a nonspecific effect on BBB permeability, particularly examining effects on paracellular transport and tight-junction integrity, the CNS distribution of a probe molecule, 3 H-mannitol, was determined with and without the co-treatment of P85. FVB mice (male FVB, 12 to 14 weeks old) were purchased from Taconic (Germantown, NY, USA). Mice received a tail-vein injection (100 mL) of 20 mCi 3 H-mannitol in saline with or without 1% P85. At selected time points after injection, 0.5, 2, 3, and 4 h, four mice at each time point were killed and serum and whole brain (homogenate) were collected for liquid scintillation counting.
Severe Combined Immunodeficiency HIVE Model
Severe combined immunodeficiency mice (male C.B-17/ IcrCrl-scidBR, 3 to 4 weeks old) were purchased from Charles River Laboratories (Wilmington, MA, USA). Animals were housed in sterile microisolator cages under pathogen-free conditions in the Department of Comparative Medicine at the University of Nebraska Medical Center in accordance with ethical guidelines for the care of animals set forth by the National Institutes of Health. Human MDM for mouse injections were cultured in suspension in 250 mL Teflon flasks (1.5 Â 10 8 cells per flask) and infected with the HIV-1 ADA at MOI of 0.01 infectious viral particles/ target cell for 6 h. At 18 h after virus infection, animals were stereotactically inoculated with 15 ml of cell suspension containing 3.0 Â 10 5 HIV-1-infected cells (in serum-free Dulbecco's modified Eagle's medium) into the left hemisphere with coordinates previously determined (Persidsky et al, 1996) . Intracranial inoculations of HIV-1 ADA infected MDM were performed following anesthesia (intraperitoneal injections of 100 mg/kg ketamine and 16 mg/kg xylazine). Animals were killed at 7 or 14 days after inoculation for immunohistochemical analyses.
Drug Treatment of HIVE Mice
Mice received ART (AZT (20 mg/kg/day), 3TC (20 mg/kg/day) and NEL (50 mg/kg/day) via intraperitoneal injections (twice a day). Drug administration was started one day before the infected MDM were injected and continued at the identical dosing regimen until animal was killed. To show specificity of the P85 P-gp mediated effect, control animals and animals treated with ART received another Pluronic block copolymer, F127, that had no effect on P-gp function (Batrakova et al, 2003) as a control for P85. Four treatment groups in the first experiment were as follows: control (untreated, 1% F127 Pluronic only, n = 6), 1% F127 and ART (n = 6), 0.2% P85 (n = 5) or 1% P85 with ART (n = 5). In a subsequent experiment, the four treatment groups were: control (F127 Pluronic control only, n = 10), F127 with ART (n = 10), 0.2% P85 alone (n = 10) and 0.2% P85 with ART (n = 10).
Immunohistochemical Analyses
Tissue was fixed in 4% phosphate-buffered paraformaldehyde and paraffin embedded. Immunohistochemistry was performed on 5 mm paraffin sections. Human MDM were identified immunohistochemically with antivimentin mAbs (1:1000 Boehringer Mannheim). The level of infection in MDM was assessed using anti-HIV-1 p24 mAbs (Dako, 1:10). Mouse astrocytes were recognized with polyclonal Abs against glial fibrillary acid protein (GFAP; 1:1000, Dako). Structural tightness of the BBB was evaluated by immunostaining with Abs to occludin and claudin-5 (tight junction proteins expressed on brain microvascular endothelium, 1:25 and 1:50, respectively, Zymed Laboratories). To detect primary Abs (vimentin, GFAP, HIV-1 p24, claudin-5 and occludin) on paraffin sections, immunoperoxidase staining was performed (Vectastain Elite ABC kit, Vector Laboratories) with 3,3 0 -diaminobenzidine as the chromogen. All sections were counterstained with Mayer's hematoxylin. Deletion of the primary antibody or use of mouse IgG or rabbit IgG (Dako) served as controls. Immunostained tissues were analyzed with a Nikon Eclipse 800 microscope.
For histologic analysis, 40 initial sections (20 sections each from two blocks) were cut from each mouse brain, and every sixth section was stained for GFAP to identify the site of injection as described (Limoges et al, 2000 . Every seventh section was stained for vimentin to detect human MDM. If the injection site or the presence of human cells was not determined, 30 more sections were cut until the injection site was determined or all of the tissue was sectioned. Each brain section containing MDM and a paired section were labeled with antibody to HIV-1 p24 antigen to generate the percentage of HIV-1-infected MDM. Results were averaged for each mouse and treatment group.
Statistical Analysis
In vitro data were analyzed by Microsoft Excel 2002 using the two-tailed nonparametric t-test. A minimum P-value of 0.05 was estimated as significant for all tests. In vivo statistical analysis was performed using GraphPad Prism software with using the two-tailed nonparametric t-test and two-way ANOVA with Newman-Keuls post-test for multiple comparisons. All in vitro and in vivo data are presented as mean7standard error of mean (s.e.).
Results
Effects of P85 In Vitro
Since mononuclear phagocytes (macrophages and microglia) are the predominant cell type infected in the human brain (Koenig et al, 1986) , we first analyzed the antiretroviral effects of P85 in combination with the protease inhibitor NEL in vitro in human MDM infected with HIV-1 ADA (a macrophage-tropic strain). We first established what concentrations of P85 are cytotoxic for MDM in vitro. Using the MTT assay, we showed that P85 significantly decreased MDM viability at concentrations > 0.1% while lower concentrations were not cytotoxic over a period of 2 weeks (data not shown).
Potential antiretroviral activities of P85 alone were next investigated at concentrations from 0.001% to 0.01%, those known not to elicit cytotoxicity. NEL alone administered at concentrations from 0.001 to 0.1 mmol/L served as a positive control. Progeny virion production from infected cells was analyzed by RT activity over a period of 12 days. As seen in Figure 1A (RT activity adjusted to MTT), P85 at concentrations from 0.001% to 0.01% decreased HIV-1 replication without any evidence of cytotoxicity. P85 showed significant inhibition of viral replication from day 5 (P < 0.01) until day 12 (P < 0.001), as compared with control. NEL administered at concentrations of 0.001, 0.01, and 0.1 mmol/L showed significant antiretroviral effect from day 5 (P < 0.001) to day 12 (P < 0.01) when compared with untreated MDM. NEL administered at a concentration of 0.001 mmol/L was able to decrease viral replication on days 5, 9, and 12 (P < 0.01) ( Figure  1B ). Lower concentrations of NEL had little effect on viral growth in these assays (data not shown).
Because of the significant antiviral effect of P85 alone shown in our initial experiment, we again examined P85 alone in a separate experiment at concentrations from 0.01% to 0.001% and combined with NEL at concentrations 0.01 to 0.001 mmol/L at day 12. The P85 alone group, as seen in Figure 1C , confirmed a significant (P < 0.001) antiviral effect with 0.001% P85, reducing HIV-1 replication to 55% of the control, and 0.01% P85 had a similar effect, reducing growth to 44% as compared with control at day 12 in this analysis. NEL at concentrations 0.01 and 0.001 mmol/L suppressed viral replication to 64% and 38% of control, respectively. NEL at concentrations 0.01 and 0.001 mmol/L combined with 0.001% of P85 decreased RT levels 52% and 45% of control untreated cells, respectively. P85 at a concentration of 0.01% in combination with 0.001 and 0.01 mmol/L of NEL diminished virus replication to 41% and 29% of control. P85 in combination with NEL showed an additional inhibitory effect in high doses (0.01% P85 and 0.01 mmol/L NEL) when compared with pluronic or protease inhibitor alone. Results of these experiments showed the significant antiviral effect of P85 alone and the presence of an enhanced effect of NEL when combined with P85 at the highest tested concentration (0.01% P85).
Effects of P85 on Blood-Brain Barrier Integrity
The brain-to-blood ratio of tritiated mannitol was determined with and without P85 co-treatment. Mannitol can be used as a permeability marker because it has a very low permeability across the BBB due to intact tight junctions, and in the time frame of the experiment, this probe molecule will have limited brain penetration as long as tight junctions are not compromised. As seen in Figure 2 , the coadministration of P85 did not dramatically enhance the distribution of mannitol into the brain, indicating that P85 did not influence the BBB integrity. The brain-to-blood area under the curve ratio was 8% in the control case and 10% in the P85-treated case. 
Antiretroviral Effects of P85 and Antiretroviral Therapy in the Severe Combined Immunodeficiency HIV-1 Encephalitis Mouse Model
We next utilized the HIVE SCID mouse model to compare the efficacy of a protease inhibitor-containing ART regimen with and without P85 on HIV-1 replication in brain. This model recapitulates the pathologic and pathophysiological features of human HIVE (including giant cell encephalitis, neuronal injury, neuroinflammatory responses and cognitive abnormalities showed in human disease (Persidsky et al, 1996; Zink et al, 2002) ). Moreover, the model allows testing of antiretroviral drugs for therapeutic efficacy in preventing viral spread in a BBB protected CNS (Limoges et al, 2000 .
First, we examined the effect of ART (AZT (20 mg/ kg/day), 3TC (20 mg/kg/day), and NEL (50 mg/kg/ day)) with or without P85 (concentrations of 0.2% or 1.0%, corresponding to < 0.01 and < 0.05% in peripheral blood, assuming simple dilution by blood volume). No toxic effects (including weight loss, appearance of animals) were detected in animals treated with ART, P85 alone, or the combination of both. Monocyte-derived macrophages were infected for a longer period of time (6 h) than in our previous experiments to ensure high levels of infection and to detect effects of P85. HIV-1 p24 antigen positive cells were detected in serial sections and the percentage of immunopositive cells averaged for each treatment group. Equal numbers of MDM were detected in the brains of animals in each of the groups (Figures 3A and  3D ). There was no significant difference in percentage of HIV-1 p24 positive MDM between control mice (52%78.9%) and the drug-only group (36%7 11.4%) at day 7 ( Figure 3G ), while the level of infection was dramatically lower when compared with control in both groups when ART were combined with P85 at 0.2% or 1.0% (3.3%73.4% and 2.8%73.4%, P < 0.001 and P < 0.001, respectively; Figures 3B, 3E, and 3G) .
Our second in vivo study was performed to address the issue of possible antiviral effects of P85 alone (as indicated by our in vitro data); and to corroborate the results of the first in vivo experiment. In the second in vivo study, P85 was examined only at the lower concentration of 0.2% alone or in combination with ART. The antiretroviral drugs were dosed at the same concentrations (AZT (20 mg/kg/day), 3TC (20 mg/kg/day) and NEL (50 mg/kg/day)) as the first experiment. Figure 4 shows results (the percent of MDM positive for HIV-1 p24 averaged for each treatment group) at days 7 and 14. The spread of viral infection in human MDM in mouse brain occurred effectively, and 39.9%710.3% and 68.5%77.9% of MDM were HIV-1 p24 positive at day 7 and day 14. At day 7, the combined ART with 0.2% P85 group showed a significant decrease of infected MDM (9.4%78.6% versus 39.9% in control, P < 0.001). The group treated with ART alone also showed significant decrease in the level of infection (13.1% + 3.5%, P = 0.028) as compared with control, while the P85 alone group was not significantly different from control (P > 0.05). At day 14, all treatment groups featured a significant diminution in the level of infection as compared with control. Although the ART reduced the percent of HIV-1 p24-positive cells (35.3%75.6%, P < 0.001), the most notable effect was achieved in the 0.2% P85 alone group (13.4%7 5.6%, P < 0.001) and the combined ART + 0.2% P85 group (7.0%710.0%, P < 0.001) when compared with control (68.577.9%) ( Figures 4A-4H) . The antiretroviral effect seen in these groups was greater than the ART group for 0.2% P85 alone (P < 0.01) and for the combined ART + 0.2% P85 group (P < 0.05).
We next evaluated neuro-inflammatory responses (astrogliosis) and preservation of the BBB in the SCID mice. This was done first to evaluate drug toxicity and second to determine the relationships between viral inhibition and neuropathology. The level of astrogliosis (as detected by GFAP staining) was not altered in different treatment groups as compared with control ( Figures 3C and 3F) . Moreover, there was no evidence of BBB disruption about the expression and distribution of tight junction proteins (claudin-5 and occludin) at any time point regardless of treatment, as assessed by immunostaining in brain microvascular endothelial cells of the SCID mice ( Figures 5I-5L) . These results indicate the absence of significant toxic effects on the BBB of P85 in the doses used in our experiments. Moreover, before any dosing of ART or P85, we examined the effect of twice-daily intraperitoneal injections for 14 days of saline control, 0.2% and 1% P85 solutions on animal weights. There were no significant differences in the weights of the mice amongst all treatment groups (data not shown).
Discussion
Despite the diminished incidence of HIV-1 associated-dementia in the ART era (Maschke et al, 2000) , the greater life expectancy of infected individuals has resulted in an increased prevalence of disease. Antiretroviral failures occur commonly and represent a particular problem for treatment of brain infection. Indeed, inefficient penetration of antiretroviral drugs into the CNS and ART failure de novo could contribute to viral mutation and sustained viral replication in brain (Jellinger et al, 2000; Sacktor et al, 2001) . Therefore, development of new approaches to improve the CNS delivery and efficacy of ART (including novel drug delivery systems) is necessary to improve the targeted efficacy of current drug therapies within the brain sanctuary. Our initial investigation began with the objective of determining if the inclusion of the block co-polymer P85 could improve efficacy of ART. Previous studies with HIV-1 protease inhibitors showed that P-gp could alter the distribution of NEL across the BBB and that inhibition of P-gp increased the brain levels of NEL to plasma levels in mice (Choo et al, 2000; Kim et al, 1998; Savolainen et al, 2002) . However, to date, no study has been reported that examined the efficacy of combination HIV-1 antiviral drugs and P-gp inhibition in human HIV-1 infected macrophages (the main cell type infected in human brain tissue) located behind an intact, functioning BBB.
P85 was chosen as the P-gp inhibitor based on previous in vitro and in vivo studies demonstrating that P85 treatment increased the permeability of Pgp substrates across primary cultures of bovine brain microvessel endothelial cells (Batrakova et al, 1999) and increased the brain penetration of digoxin (a known P-gp substrate) in mice to a comparable degree as seen in P-gp knockout mice (Batrakova et al, 2001b) . The protease inhibitor NEL, with poor CNS penetration, is part of current ART regimens. Our in vitro study showed that NEL significantly lowered HIV-1 replication in human MDM when compared with control untreated cells. An unexpected result was the previously unknown antiviral effect of P85 when administered independently of NEL. The combination of P85 with NEL was no more efficient in decreasing HIV-1 replication when compared with the NEL alone group, with the exception of the 0.01 mmol/L NEL-0.01%P85 group, Figure 4 Effect of P85 (0.2%) and triple drug combination (ART) on viral replication in HIVE SCID mice. At day 7, the combined ART-P85 and ART alone groups showed a significant decrease of HIV-1 p24 expressing MDM (9% and 13%, resp.) while the P85 alone was not different from control. At day 14, the most notable effects were seen in the P85 alone group and the combined drug/P85 group (6% to 15% of HIV-1 p24positive MDM), which were superior to the NEL/AZT/3TC (ART) group (35% p24-positive cells). Histologic data from all mice were analyzed and the percent of MDM expressing HIV-1 p24 was averaged for each treatment group. Bar values represent means7s.e. which showed a significant enhanced effect (see Figure 1C ). These results suggest that P85 has significant antiretroviral effect in nontoxic concentrations.
To confirm these in vitro observations, we utilized the SCID mouse model for HIVE where spread of HIV-1 infection between human MDM was shown (Limoges et al, 2000) . This model was previously used for comparative assessment of different antiretroviral drugs by measurements of viral load and numbers of infected human macrophages (Limoges et al, 2000 . Our first in vivo experiment showed that the combination of P85 (0.2% and 1%) with ART (AZT, 3TC, and NEL) in doses used effectively in humans suppressed viral replication at significantly higher levels when compared with triple drug therapy alone. Importantly, the control group and drug only group were treated with another block co-polymer (F-127), which lacks P-gp inhibitory properties (Batrakova et al, 2003) . These results supported our initial idea that P-gp inhibition can result in efficient drug delivery across the BBB in the setting of HIV-1 infection. Because of the major reduction of viral replication detected in the first in vivo experiment with the combination of ART plus P85 and the unexpected effect of P85 in the in vitro experiment, a second in vivo experiment was designed to determine the effect of P85 alone. It included the same control, drug combination alone, and the combination of ART with 0.2% P85, but with the addition of a 0.2% P85 alone group. Similar to our first in vivo study, there was a decrease in the percentage of HIV-1 virus in MDM with the combination drugs and drugs combined with 0.2% P85 at days 7 and 14. The important finding was that P85 alone was able to suppress viral replication in MDM by day 14. Of note, no significant toxic effects or signs of BBB breakdown were found in any of the treatment groups in vivo.
Our results show that the inhibition of P-gp using the copolymer P85 may have effects other than just increasing the penetration and efficacy of antiretroviral drugs into the CNS. Recent studies indicated that P-gp could play an important role in HIV-1 replication because of the association of P-gp with glycolipid membrane domains (Speck et al, 2002) . Both viral infection and HIV-1 budding occur in cholesterol-enriched microdomains, known as lipid 'rafts' (Ono and Freed, 2001; Popik et al, 2002) . It has been suggested that cellular receptors used by HIV-1 to infect macrophages (CD4 and CCR5) are located within lipid-rich rafts (Ono and Freed, 2001; Popik et al, 2002) . Since the effects of P85 on plasma membranes have been shown to include decreased microviscosity of the membrane (Batrakova et al, 2003) , this co-polymer may disrupt rafts and influence receptor distribution. Of note, P-gp is predominately localized in these cholesterolenriched areas (Luker et al, 2000) . Furthermore, P-gp mediates the ATP-dependent relocation of cholesterol from the cytosolic leaflet to the exoplasmic leaflet of the plasma membrane (Garrigues et al, 2002). Therefore, we hypothesize that the decrease in HIV-1 replication with 0.2% P85 alone may be caused by an interaction with P-gp or directly with the glycolipid enriched rafts. This hypothesis requires further investigation.
The in vivo anti-HIV1 activity of P85 in the CNS strongly suggests that P85 crosses the blood-brain barrier. This was confirmed in a recent study of the biodistribution of radiolabeled P85 in the mouse (Batrakova et al, 2004) . In that study, the distribution of P85 to the brain was proportional to an intravenous dose of 100 mL 0.02%, 0.2% and 1.0% P85 injected as a bolus in the tail vein.
One advantage of using the Pluronic block copolymer P85 as a P-gp inhibitor is that potentially it has two mechanisms of action (Batrakova et al, 2001a) . As reported by Batrakova et al (2001a) , P85 decreased ATP levels in bovine brain endothelial cell monolayers, an effect that would be important due to the need for ATP for the late stage processing of HIV-1 (Tritel and Resh, 2001) . The structure of lipid bilayers can also be affected by P85 because of absorption of the block copolymer molecules in the membrane, which may lead to the destabilization of P-gp (Batrakova et al, 2001a) . It is feasible that the P85-mediated antiviral effect seen in our in vitro and in vivo experiments could be associated with destabilization of lipid rafts. Alteration of the lipid membrane environment has been shown to be crucial to the function of P-gp (Romsicki and Sharom, 1999) . Membrane fluidization by various agents such as Tween-20, Nonidet P-40, and Triton X-100 has also been shown to inhibit P-gp efflux (Regev et al, 1999) .
Discrepant results of our in vitro experiments (i.e., the absence of enhanced effect of NEL combined with P85 except at the high concentrations) and the increased in vivo efficacy of the P85 and ART combination could be related to the inhibition of other efflux transporters on the BBB by P85. These include multidrug resistant-associated proteins 4 and 5 (MRP4, MRP5) present on BBB and breast cancer resistant protein, which has been recently shown on brain microvascular endothelial cells (Eisenblatter et al, 2003; Zhang et al, 2003 ) and brain macrophages (Persidsky et al, 2006) . This possibility and other potential mechanisms underlying the anti-HIV-1 effect of P85 are currently under investigation in our laboratories.
The early rationale for using inhibitors of P-gp with HIV-1 protease inhibitors was to increase their limited distribution across biologic barriers into HIV-1 sanctuary sites such as the CNS (Choo et al, 2000; Kim et al, 1998; Savolainen et al, 2002) . This study for the first time indicates that P-gp inhibition may also be important in decreasing HIV-1 replication and is concordant with current understanding of cellular requirements for HIV-1 replication (Speck et al, 2002; Tritel and Resh, 2001) . We showed that P-gp inhibition may not only increase efficacy by increasing drug distribution into blood-tissue barriers of HIV-1 virus, but that P85 itself could also have an antiretroviral effect in particular cell targets (like macrophages) serving as a viral reservoir in the CNS. In this regard, further studies are needed to examine the drug concentrations of the antiretrovirals in the brain to determine if P85 may increase penetration of ART to the brain. The possible dual inhibitory nature of P85, either by ATP depletion or membrane fluidization, also needs to be clarified. This study presents a new direction to solve problems of anatomic and cellular sanctuary sites for HIV-1 replication (Pomerantz, 2002; Schrager and D'Souza, 1998) .
